Amneal Pharmaceuticals, Inc. $AMRX Holdings Decreased by Rubric Capital Management LP

Rubric Capital Management LP decreased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 10.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,037,589 shares of the company’s stock after selling 1,297,352 shares during the period. Amneal Pharmaceuticals comprises about 1.5% of Rubric Capital Management LP’s portfolio, making the stock its 17th largest holding. Rubric Capital Management LP’s holdings in Amneal Pharmaceuticals were worth $137,197,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the stock. Kemnay Advisory Services Inc. acquired a new stake in Amneal Pharmaceuticals in the fourth quarter worth $26,000. Federated Hermes Inc. increased its position in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Comerica Bank increased its position in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Spire Wealth Management raised its stake in Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after acquiring an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC raised its stake in Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Barclays upped their price objective on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Finally, UBS Group boosted their price target on shares of Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $18.09 on Tuesday. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $18.39. The stock has a market cap of $5.77 billion, a PE ratio of 47.61 and a beta of 1.26. The business’s fifty day moving average is $15.72 and its 200-day moving average is $14.11.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The business had revenue of $722.52 million during the quarter. Equities research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.